RSI Alert For Infinity Pharmaceuticals (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Tuesday, shares of Infinity Pharmaceuticals Inc ( INFI) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15.97 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 42.2. A bullish investor could look at INFI's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of INFI shares:

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

Infinity Pharmaceuticals Inc 1 Year Performance Chart

Looking at the chart above, INFI's low point in its 52 week range is $15.45 per share, with $50.51 as the 52 week high point — that compares with a last trade of $16.01.

According to the ETF Finder at ETF Channel, INFI makes up 1.56% of the SPDR S&P Biotech ETF ( XBI) which is trading lower by about 5.6% on the day Tuesday.
null

If you liked this article you might like

Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy

5 Stocks Insiders Love Right Now

Infinity Pharmaceuticals (INFI) Stock Rises on 'Favorable' Cancer Drug Trial Results

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

Infinity Pharmaceuticals (INFI) Highlighted As Weak On High Volume